Tirofiban

Tirofiban
Clinical data
Trade names	Aggrastat
AHFS/Drugs.com	Monograph
MedlinePlus	a601210
License data	US DailyMed: Tirofiban;
Pregnancy; category	AU: B1;
Routes of; administration	intravenous
ATC code	B01AC17 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	65%
Elimination half-life	2 hours
Identifiers
CAS Number	144494-65-5 ;
PubChem CID	60947;
IUPHAR/BPS	6586;
DrugBank	DB00775 ;
ChemSpider	54912 ;
UNII	GGX234SI5H;
KEGG	D08607 ;
ChEBI	CHEBI:9605 ;
ChEMBL	ChEMBL916 ;
CompTox Dashboard (EPA)	DTXSID20162730 ;
ECHA InfoCard	100.163.548
Chemical and physical data
Formula	C22H36N2O5S
Molar mass	440.60 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N[C@H](C(=O)O)Cc2ccc(OCCCCC1CCNCC1)cc2)CCCC;
	InChI InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1 ; Key:COKMIXFXJJXBQG-NRFANRHFSA-N ;
	(verify)

Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.^[2]^[3]

It is available as a generic medication.^[4]

^ "Aggrastat- tirofiban injection, solution". DailyMed. Retrieved 19 June 2021.
^ Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, et al. (November 1992). "Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors". Journal of Medicinal Chemistry. 35 (24). American Chemical Society: 4640–2. doi:10.1021/jm00102a020. PMID 1469694.
^ Van Drie JH (2007). "Computer-aided drug design: the next 20 years". Journal of Computer-Aided Molecular Design. 21 (10–11). Springer: 591–601. Bibcode:2007JCAMD..21..591V. doi:10.1007/s10822-007-9142-y. PMID 17989929. S2CID 3060340.
^ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[Aggrastat_FDA_label-1] "Aggrastat- tirofiban injection, solution". DailyMed. Retrieved 19 June 2021.

[HartmanGD-2] Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, et al. (November 1992). "Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors". Journal of Medicinal Chemistry. 35 (24). American Chemical Society: 4640–2. doi:10.1021/jm00102a020. PMID 1469694.

[VanDriesJ-3] Van Drie JH (2007). "Computer-aided drug design: the next 20 years". Journal of Computer-Aided Molecular Design. 21 (10–11). Springer: 591–601. Bibcode:2007JCAMD..21..591V. doi:10.1007/s10822-007-9142-y. PMID 17989929. S2CID 3060340.

[4] "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[1]

[2]

[3]

[4]